Introduction
Gaucher disease is a rare autosomal recessive disorder that is characterized by reduced amounts of the enzyme betaglucocerebrosidase, leading to variable metabolic disease. Onset is often in childhood or early adulthood. Adults with non-neuropathic type 1, the most common type and frequently with late onset, may not be aware of having Gaucher disease and may be asymptomatic or have only mild manifestations; studies report that only about one-third of adults, who are in their second or third decades and at risk for Gaucher disease, report having symptoms (Beutler et al., 1993; Balwani et al. 2010) . Symptoms can range from mild to severe, and most often include bone disease, spleen and/or liver enlargement, and anemia (Charrow et al. 2000; Grabowski 2000) . Enzyme replacement therapy is used to treat type 1 and may eliminate many of the symptoms of Gaucher disease. However, enzyme replacement therapy may not reverse or prevent progression of neurological complications associated with the more severe types (Barton et al. 1991; Lee et al. 2014) . Early in the last century, Brill described the familial nature of the disorder (Brill 1901) , and in 1989, glucosylceramidase beta (GBA) was identified as the causative gene (Ginns et al. 1984; Sorge et al. 1985) . Since then over 300 mutations in the GBA gene have been discovered (Hruska et al. 2008) .
Parkinson disease is a common neurodegenerative disorder with an average age of onset of 60 years (Reider et al. 2003) . Parkinson disease is caused by reduced levels of dopamine in specific neurons of the brain and has three hallmark clinical features: rigidity, bradykinesia, and tremor. Non-motor symptoms such as sleep disorder, mood problems, and cognitive changes, are also important components of this disorder. There is currently no cure for Parkinson disease nor a treatment that reliably slows the progression; however, there are medications and surgical options that can improve the symptoms (Oertel and Schulz 2016) . While Parkinson disease is not a classically genetic condition, genetic risk factors have recently been identified. Some of the first genes implicated in causing Parkinson disease include the SNCA1 gene that encodes alpha-synuclein, and leucine-rich repeat kinase 2 (LRRK2), a gene that, when mutated, is an important contributor to Parkinson disease worldwide (Lesage et al. 2005; Polymeropoulos et al. 1997; Zimprich et al. 2004) . The GBA connection to Parkinson disease would not be discovered until a few years later (E. Sidransky et al. 2009 ). Both Parkinson disease and Gaucher disease are found at a greater frequency in those of Ashkenazi Jewish ancestry (Ellen Sidransky and Lopez 2012).
The Link-Gaucher Disease and Parkinson Disease
These two disorders, at first glance, may seem unrelated; however, cases have emerged of patients with Gaucher disease developing neurological complications later in life, including features of Parkinson disease (Neudorfer et al. 1996; Tayebi et al. 2001) . Sequencing of the GBA gene was performed in a series of 17 patients who had Gaucher disease and parkinsonism, all of whom had various GBA mutations including the common N370S variant. On autopsy, four of these patients had evidence of alpha-synuclein-rich Lewy bodies in the brain -a pathognomonic feature of Parkinson disease. It was concluded that the risk for parkinsonism could be attributed to glucocerebrosidase deficiency and that there were similar clinical and neuropathologic features in these patients suggesting an underlying link (Tayebi et al. 2003) . Later in the neurology realm, it was found that approximately 7-15% of individuals with Parkinson disease carry a GBA mutation, with higher rates in Ashkenazi Jews (E. Sidransky et al. 2009 ).
We now know that that carriers of Gaucher disease, have approximately a 4-fold increased chance of developing Parkinson disease compared to the general population Rana et al. 2013 ). In the study by Rana and colleagues, the cumulative risk of Parkinson disease in carriers of Gaucher disease, mostly Ashkenazi Jewish, was 10.9% by age 85 (Rana et al. 2013) . Data from the International Collaborative Gaucher Group (ICGG) Registry reported a 9-12% risk of parkinsonism by age 80 in patients with Gaucher type 1 (Rosenbloom et al. 2011) . Thus, it is established that these two conditions are surprisingly linked. A single GBA mutation actually carries two different risks: one reproductive and the other for personal health.
Additional research highlights a possible link between carriers of GBA mutations and specific features of Parkinson disease including an earlier age of onset, symmetrical involvement of motor features, and higher risk of cognitive symptoms, including Lewy body dementia. Recent meta-analysis and trio analysis also suggest that carriers of severe GBA mutations may have an even greater overall risk for Parkinson disease and related complications than those with the milder N370S mutation (Gan-Or et al. 2015; Arkadir et al. 2016) . Accumulating data continue to show that carriers of GBA mutations are at a higher risk than the general population of developing Parkinson disease in their lifetimes, with the potential for additional complications or specific symptomatology.
Intersections of Gaucher and Parkinson Disease: The Encounter
It is not clear how this information about the link between Gaucher and Parkinson disease has been translated and applied in various genetic counseling or other settings. There are many environments, both clinical and non-clinical, where GBA and Gaucher testing is being performed, and a variety of scenarios in which carriers of GBA mutations may be identified (Table 1 ). States such as Missouri and Illinois have begun Gaucher disease screening through their newborn screening program as part of the lysosomal newborn screening panel, with other states following close behind, and individuals with Gaucher disease and/or obligate carriers of GBA mutations will likely be identified in increasing numbers (http://health. mo.gov/living/families/genetics/newbornscreening/ publications.php; http://www.dph.illinois.gov/topics-services/ life-stages-populations/newborn-screening/metabolicscreening). Active recruitment of carriers of GBA mutations for clinical trials, initiatives led by advocacy groups, large carrier screening programs, expansion of direct-to-consumer testing (DTC), and expansion of newborn screening all increase identification of carriers of GBA mutations in other settings where additional education may be needed.
Dissemination of information regarding the Gaucher and Parkinson disease link could potentially occur in these different places and in varied ways. Informal discussions among metabolic, prenatal, and clinical research genetic counselors were held addressing this topic as part of our project initiatives including recruitment efforts to Gaucher clinics. It was noted that genetic counselors may have varied levels of knowledge about the association and different levels of comfort in regard to discussing Parkinson or Gaucher disease, especially if this is not the primary indication for referral. Practices of several genetic counselors were queried and differences found in disclosure among centers. In nontraditional/nonclinical settings where genetic testing occurs, there may not be trained staff such as genetic counselors to inform protocols and practice as we experienced in our project, initially. This may further increase the variability in the dissemination of information about the link. Further research is needed to address the larger question: when is it appropriate and relevant to make this connection -a rare, autosomal recessive metabolic disease typically occurring in younger individuals, and a common, seemingly sporadic, later-onset adult condition that features both motor and nonmotor features including cognitive impairment? In addition, what are the attitudes among health care providers and researchers regarding the need to discuss the possibility of Parkinson disease, especially GBA-associated Parkinson disease that has a potentially greater risk for dementia, or depending on the setting, the need to discuss Gaucher disease (Ellen Sidransky and Lopez 2012)? What are the practices of health care providers in initiating discussion, when the consideration of Parkinson disease or Gaucher disease risk may be a secondary topic shadowed by larger primary concerns? Furthermore, the logistics of transmitting this information in an increasingly complex genetic testing world may add another potential barrier and level of complexity that need to be investigated.
Lack of Knowledge of the Gaucher-Parkinson Connection: The Indiana University Parkinson's Progressive Markers Initiative (PPMI) Experience
PPMI is a large observational clinical study that in part, recruits participants who carry Parkinson disease-associated mutations to search for potential biomarkers for Parkinson disease progression (Foroud et al. 2015) . Major qualifications for the study are Ashkenazi Jewish ancestry and a personal or family history of Parkinson disease. Genetic counselors disclose results following informed consent and genetic testing, providing post-test genetic counseling by telephone. Initially, the study involved genetic testing for a major LRRK2 variant, but since then has expanded to include the common N370S GBA variant in order to increase the mutation yield. (Although there are additional GBA variants that could be tested, the most common variant was chosen due to cost considerations.) Currently, over 3000 individuals have been screened and counseled; this includes identifying and counseling over 350 carriers of GBA variants. More recently, as part of our GBA variant recruitment, we have contacted Gaucher clinics and foundations to inform them about our study and to provide contact information to their patients. Referrals from DTC companies are also received, whose participants have been have been informed about the study as part of their testing for genetic health risk factors.
The addition of GBA testing and novel recruitment strategies have created a need to review study protocols and • Genetic counseling may not be available in all clinics.
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processes. It was realized that by identifying carriers of GBA mutations with increased risk for Parkinson disease, individuals were also being identified as carriers of Gaucher disease. It was decided that information about Gaucher disease should be provided as part of our counseling session, in addition to information about Parkinson disease. Two primary reasons were: the possibility that a targeted genetic analysis would miss a second, less common GBA mutation that could cause Gaucher disease in an individual, and the implications of reproductive risk to participants and their relatives. A fact sheet was developed to send to participants after their sessions that specifically discusses the association of GBA mutations with both Parkinson disease and Gaucher disease (Appendix 1).
While providing education about Gaucher and Parkinson disease as part of the telephone counseling sessions, the counselors were surprised by the lack of baseline knowledge about this connection. Occasionally, participants were encountered who were identified as carriers of a GBA variant through carrier screening; however, they did not make a connection of that test result to our study nor seemed aware of the Parkinson disease risk prior to our discussion. A typical comment was BI knew I (or my children) had the Gaucher mutation but did not know it was the same gene that can cause Parkinson's^. A few families presented with a history of both Gaucher disease and Parkinson disease, and were usually unaware, prior to counseling, that these two conditions were related. In testing families with a known history of Parkinson disease, we have uncovered at least 5 homozygous carriers of GBA, who presumably have Gaucher disease, and were completely unaware of the potential for Gaucher disease within their family or themselves. Preliminary observation suggests that either health care providers are not discussing this information about the link of the two diseases and/or patients do not recall this information.
Current Recommendations and Practices for Disclosure of the Gaucher and Parkinson Disease Link Prenatal and Carrier Screening
The primary recommendations for GBA gene testing pertain to the prenatal carrier screening of at-risk couples, specifically those of Ashkenazi Jewish descent. While the American College of Obstetrics and Gynecologists (ACOG) does not list Gaucher disease on their recommended list of diseases for which carrier screening should be offered, this disease is included in a list of Bother disorders^for which families can request screening and providers should provide educational materials for informed decision-making (ACOG 2009). The American College of Medical Genetics (ACMG) statement goes a step further in adding Gaucher disease, as well as four other diseases to their recommended carrier screening panel.
When discussing educational and clinical issues related to carrier screening, both the ACOG and ACMG statements review the possibility of discussing the variable onset and severity of Gaucher disease, however, neither statement mentions the potential health implications for identified carriers. Due to the rapid availability of expanded carrier screening, additional recommendations were outlined in 2015 by the ACMG, ACOG, National Society of Genetic Counselors (NSGC), and Society for Maternal-Fetal Medicine (SMFM), for the purpose of supplementing previous recommendations. This new position paper does outline education points such as variable phenotype and residual risk, however, no reference to adult-onset symptoms is made, and the guidelines specifically state that Bin most cases, being a carrier of an autosomalrecessive condition has no clinical consequences for the individual carrier^. For those individuals who are incidentally identified with two mutations on carrier screening with the potential for personal health risks, a referral to a specialist for management and genetic counseling is recommended (Edwards et al. 2015) .
In the study by Falcone et al., carrier screening practices for Gaucher disease were measured; they reported that greater than 80% of prenatal health care providers are offering Jewish carrier screening, which often includes GBA testing, to couples of Ashkenazi Jewish ancestry. Thus, carrier screening for Gaucher disease is being offered frequently within this context. Most genetic counselors and physicians stated that patients are educated about Gaucher disease prior to screening, whereas midwives usually provide education after screening. The authors recognized the need to evaluate how Gaucher disease screening services should be provided including a discussion of Parkinson disease (Falcone et al. 2012 ).
Metabolic/Gaucher Clinics
No guidelines by professional groups were located describing the discussion of the Gaucher-Parkinson link. In the published article by Sidransky et al., it is suggested that genetic counseling for Parkinson disease risk in individuals with Gaucher disease and carriers is complicated and should be done with care. Recommendations are made for clinical evaluation and detailed medical and family history intake relating to Parkinson disease in these families (Ellen Sidransky and Lopez 2012).
Neurology/Neurogenetics Clinics
Specific to neurology, no guidelines by professional groups were located. Swan and colleagues make the recommendation that patients who are identified as being homozygous or compound heterozygous for GBA mutations within a neurology setting be evaluated further for features of Gaucher disease (Swan and Saunders-Pullman 2013) . Sakanaka and colleagues stress the importance of educating individuals with Parkinson disease and their caregivers about the genetics of Parkinson disease, such as the role of GBA mutations, and the implications of results on relatives ).
General Genetic Testing Recommendations and Secondary Findings
In genetics, secondary findings (SFs) are defined as additional test results relating to health that are discovered during the evaluation of another clinical indication. Typically, this involves another variant(s); however, the literature surrounding this broad topic may provide some foundation for fashioning specific guidelines regarding disclosure about secondary disease associations for a GBA variant (R. C. Green et al. 2013; Hegde et al. 2015; Richards et al. 2015; Kalia et al. 2016) . Patient preference, medical actionability, age considerations, and variants proven to be associated with monogenic rather than complex disorders are important considerations in this context (R. C. Green et al. 2013; Kalia et al. 2016; Scheuner et al. 2015) .
Baseline Knowledge and Preferences for Disclosure in Participants/Patients and their Families
A few studies provide preliminary evidence that participants of studies, patients, and caregivers are interested in learning about GBA related-conditions as additional or secondary findings (Brothers et al. 2016; Sakanaka et al. 2014) . A study of 533 individuals, comprised of individuals with Parkinson disease and their caregivers, found that 93% were interested in hearing results related to Gaucher disease as part of their genetic testing for Parkinson disease. Of note is that after receiving information about Gaucher disease, GBA mutations, and relationships to Parkinson disease, there were gaps in knowledge scores on testing, suggesting more education about the implications of genetic testing is needed ). Brothers and colleagues recruited families from a pediatric neurology clinic to explore their preferences in receiving SFs identified by genomic sequencing. Thirteen categories of conditions representing secondary results were provided, including Parkinson disease. They reported that over 90% of participants would be likely to request secondary results regarding Parkinson disease (Brothers et al. 2016 ).
In summary, for most specialties where Gaucher disease and Parkinson disease cross paths, there is minimal formal guidance for health care providers as to whether the connection should be discussed and in what manner. Preliminary data suggest that in some situations, patients and their families may be interested in more information (Brothers et al. 2016; Sakanaka et al. 2014) . There is an effort to educate the lay public by some foundations (Table 2) , though, specific recommendations on how and when to discuss this connection appear to be missing from most of the current literature with the exception of those articles referenced in this paper that begin to address this Ellen Sidransky and Lopez 2012) .
From a health care provider perspective, there may be reasons to disclose the link such as informing individuals, especially as it relates to reproductive risks, personal health, and planning for the future. Potential genetic discrimination for young adult carriers prior to obtaining life, long-term or disability insurance, which is not currently covered by the Genetic Information Nondiscrimination Act (Pub.L. 110-233, 122 Stat. 881, enacted May 21, 2008) , also known as GINA, may be yet another reason to disclose prior to carrier testing. The specialty or setting will likely determine the content of information provided. For example, identified carriers may want more information regarding reproductive risks to themselves and their relatives as well as planning for potential health outcomes. Individuals with Gaucher disease may want be alerted to early signs of Parkinson disease such as movement problems that could increase risk for falls -a concern especially if there is existing bone disease. Additionally, those with Parkinson disease, who unknowingly carry homozygous GBA mutations, can be formally screened for Gaucher disease and potentially offered treatment.
It should be noted that no medical treatments specific to GBA carriers are available for Parkinson disease. To date, enzyme replacement treatment used to treat Gaucher disease does not appear to benefit individuals with GBA mutations who develop Parkinson disease (Barkhuizen et al. 2016 ). There are no specific recommendations for screening or proactive preventative measures to take should an individual become aware of their risk for Parkinson disease through GBA testing. However, preventative strategies may be quickly approaching with rapidly moving research (Ellen Sidransky and Lopez 2012). Targeted treatment for mutation subtypes of Parkinson disease is underway in some clinical trials (https:// clinicaltrials.gov). Finally, even if we do not see an overall benefit in disclosure, our patients may think otherwise, choosing to be more fully informed (Brothers et al. 2016) .
Future Directions and Conclusion
There is now a known link between Gaucher and Parkinson disease as both have been shown to have a GBA variant(s) involved in causation. There are multiple and varied ways a GBA variant may be encountered by a health care provider and many questions may arise relating to addressing the associations of these two disorders. Guidance from professional groups or researchers as to how to inform patients about the link is currently limited. Based on experience in a large Parkinson disease research project in which hundreds of carriers of GBA mutations have been identified and counseled, there is indication that there may be insufficient knowledge and awareness about the association of Gaucher and Parkinson disease among patients. In addition, informal discussion with genetic counselors have shown that practices of disclosure may vary among providers and settings.
Suggested areas of future study would be establishing the knowledge, practice, and comfort levels of genetic counselors, other health care providers, and researchers regarding GBA associations in places where Gaucher disease and Parkinson disease are encountered, namely preconception, prenatal, metabolic, neurologic, testing, and research locations. In addition, more formal dialogue about whether and how to discuss the full implications of GBA genetic testing and carrying a mutation would be beneficial to establish recommendations for education and counseling of these individuals at risk. It would also be interesting to explore in more detail what disclosure preferences patients and families have.
As genetic counselors we are continually faced with determining how much information is needed in a specific situation to inform and empower our clients without burdening them. This becomes more difficult when it involves an additional finding that is not related to the clinical or research indication. We highlight an important topic, the disclosure of the Gaucher and Parkinson disease connection-that likely requires more expert input and guidance for multiple specialties and settings.
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Appendix 1 Fact Sheet Parkinson Disease and Gaucher Mutations
Parkinson disease is a chronic and progressive movement disorder. About 1-2% of all people will develop Parkinson disease in their lifetime. The age of onset is typically around age 60, though it can occur earlier or later. In Parkinson disease, the parts of the brain controlling movement slowly begin to lose proper function, which can result in tremors, gait impairment and other symptoms. It is important to remember that symptoms vary from person to person, as does the rate of progression. Although there is not yet a cure or way to reliably slow the progression of Parkinson disease, there are medications that can improve the symptoms.
Parkinson disease is a complex disorder. To date, the exact causes of Parkinson disease remain unknown. Scientists believe that both environmental and inherited genetic factors are involved and that the interaction between these factors is important.
DNA is our hereditary material. Every cell in our body has an almost identical copy of our DNA. Our genes are sections of our DNA. We have over 25,000 genes and each gene has specific functions. Some genes determine our hair color, eye color, or regulate how our body digests food. Other genes protect our bodies from developing diseases, like cancer or diabetes. We have two copies of every gene. One copy of each gene is inherited from our mother and the other copy is inherited from our father. When changes (mutations) are present in our genes, this can often contribute to a disease or risk of a disease.
An important gene association was made in 2009, linking mutations in the GBA gene that cause Gaucher disease with Parkinson disease. It was discovered that individuals with Gaucher disease and some of their relatives have an increased risk of developing Parkinson disease. The GBA gene instructs the body to make an enzyme called beta-glucocerebrosidase, an enzyme that breaks down a fatty substance in the body. Mutations in the GBA gene either reduce or eliminate the amount of beta-glucocerebrosidase enzyme available to break down fatty substances, causing these substances to accumulate in the body. Individuals with two mutations in the GBA gene will usually have Gaucher disease, while those with just one GBA mutation are called carriers and are not affected with Gaucher disease.
Studies have shown that individuals with a mutation in one copy (carriers) or both copies of the GBA gene (have Gaucher disease) are at an increased risk to develop Parkinson disease.
However, many people who carry GBA mutations will never develop Parkinson disease. Parkinson disease is a complex disorder, and it is likely other risk factors are needed in addition to the mutation for an individual to develop Parkinson disease.
A change in the DNA sequence (mutation) can occur anywhere with the GBA gene, and these changes are found more often among individuals with Parkinson disease. Approximately 20% of patients with Parkinson disease who are of Eastern European (Ashkenazi) Jewish descent will carry a GBA mutation, while approximately 7% of patients with Parkinson disease who are of non-Jewish ancestry will carry a GBA mutation. The most common GBA gene mutation found among individuals with Parkinson disease is the N370S mutation, however there are many other mutations that can occur. Some mutations may have a higher risk for Parkinson disease than others, and researchers are studying whether having two GBA mutations may be associated with a higher lifetime risk for Parkinson disease.
Mutations in the GBA gene are inherited or passed on through families, and therefore each person who is a carrier of a GBA mutation will have a 50% chance to pass that mutation on to each child. Individuals with Gaucher disease have two GBA mutations, one inherited from each parent; therefore, parents of a child with Gaucher disease are assumed to be carriers of at least one GBA mutation. A child of an individual with Gaucher disease will carry at least one of the GBA mutations inherited from that parent. If a person's sibling, parent, or child is known to be a carrier, then that individual is at a 50% chance of also being a carrier.
Both males and females can pass on and inherit the mutation. Only one GBA mutation is needed to have the associated Parkinson disease risk. However, most GBA carriers and individuals with Gaucher disease will not develop Parkinson disease as many factors contribute to causing Parkinson disease.
